Preclinical News and Research

RSS
DSM commences cGMP-manufacturing of Novacta's C. difficile compound

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

Discovery Labs receives FDA guidance to gain Surfaxin approval for RDS in premature infants

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial

Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial

Elotuzumab shows promise in treating multiple myeloma: Study

Elotuzumab shows promise in treating multiple myeloma: Study

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Tranzyme Pharma receives BioQuébec's 2010 Genesis Award for "Innovation"

Tranzyme Pharma receives BioQuébec's 2010 Genesis Award for "Innovation"

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.